



**Novel treatment of acute on chronic liver failure
using synergistic action of G-CSF and TAK-242**

H2020 – 945096

D7.9 – Video explaining new knowledge on G-TAK in srAH and ACLF

WP Leader	Nina Donner, PhD (11 - concentris)
Authors	Nina Donner (concentris)
Version	Final
Due date of deliverable	30/11/2025
Actual submission date	28/11/2025
Dissemination level	PU (public)

Contributors

Contributor	Contribution	Estimate of invested person months (PM)
UCL (coordinator)	<i>Speaker / presenter in video 1</i>	<i>Rajiv Jalan (0.05 PM)</i>
Charité (clinical study supervision)	<i>Speaker / presenter in video 1</i>	<i>Cornelius Engelmann (0.05 PM)</i>
	<i>Speaker / presenter in video 2</i>	<i>Julian Pohl (0.05 PM)</i>
	<i>Speaker / presenter in video 3</i>	
LUMC (early-career-scientist speaker)	<i>Speaker / presenter in video 3</i>	<i>Annarein Kerbert (0.05 PM)</i>
ELPA, patient organisation	<i>Co-planning and co-production of video 1 together with concentris</i>	<i>Marko Korenjak (0.05 PM)</i>
		<i>Beatrice Credi (0.1 PM)</i>
concentris, WP7 lead	<i>Planning, recording, and production of the videos; social media announcements and promotion of the videos on the project website; writing and submission of the report (Deliverable Report D7.9)</i>	<i>Nina Donner (0.3 PM)</i> <i>Tassilo Steinmann (0.1 PM)</i> <i>Nicholas Lupke (0.1 PM)</i>

Table of Contents

Abbreviations.....	3
1 Executive Summary.....	4
2 Introducing G-TAK, a novel combinatorial therapy for cirrhosis & ACLF (Video 1).....	5
3 Alcohol-related liver failure versus infection-induced ACLF (Video 2).....	6
4 Evolving patterns in the clinical burden of liver cirrhosis (Video 3)	7
5 Conclusion.....	8
6 Acknowledgement and Disclaimer	8

Abbreviations

ACLF	acute-on-chronic liver failure
Charité	Charité – Universitätsmedizin Berlin
concentris	concentris research management gmbh
D	Deliverable
EASL	European Association for the Study of the Liver
EC	European Commission
EF CLIF	European Foundation for the Study of Chronic Liver Failure
ELPA	European Liver Patients Association
EU	European Union
G-CSF	granulocyte-colony stimulating factor
G-TAK	combinatorial therapy of A-TANGO using G-CSF and TAK-242
LUMC	Leiden University Medical Centre
PM	person months
PU	public
TAK-242	antagonist of toll-like receptor 4 (TLR4)
TLR4	toll-like receptor 4
UCL	University College London
URL	uniform resource locator
WP	work package

1 Executive Summary

An important aspect of the [A-TANGO](#) project has been to communicate the project's scientific background, our goal of fighting acute-on-chronic liver failure (ACLF), and to explain the newest scientific outputs openly and transparently to all stakeholders, especially the patient community and clinical hepatologists. This deliverable serves the following two objectives of work package 7 (WP7) in A-TANGO's description of action (DoA), namely

- To inform and foster exchange with the scientific community and patient organisations
- To disseminate to a range of stakeholder types the results of this trial and the therapeutic potential of G-TAK

To fulfil this deliverable and explain new knowledge on A-TANGO's combinatorial therapy (G-TAK) in steroid-resistant alcoholic hepatitis (srAH) and ACLF, the consortium produced three different videos:

1. The **first video (830 views, 12,470 impressions)** was recorded and produced for YouTube as an introductory video early on to inform the patient community about the disease progression of srAH, cirrhosis, and ACLF, and to describe the anticipated physiological mechanisms and therapeutic potential of the combinatorial G-TAK therapy. The **30-min-long video** features Marko Korenjak, president of the European Liver Patients Association (ELPA), Prof. Rajiv Jalan (University College London, UCL, and EF CLIF and UCL), the scientific coordinator of A-TANGO, and Dr. Cornelius Engelmann (Charité – Universitätsmedizin Berlin), the clinical study coordinator.
2. The **second video (153 views, 2,247 impressions)** explains important A-TANGO results - revealing different clinical profiles of patients with alcohol-related ACLF versus infection-induced ACLF. The **4-min long video** features both Dr. Annarein Kerbert (medical doctor and postdoctoral researcher at Leiden University Medical Centre, LUMC) and Dr. med. Julian Pohl (medical doctor at the Charité – Universitätsmedizin Berlin) at their poster at the 2024 Congress of the European Association for the Study of the Liver (EASL) in Milan (poster THU-057-YI). The "YI" designation highlights the scientific achievements of Young Investigators at this prestigious annual liver congress.
3. The **third video (82 views, 988 impressions)** communicates new knowledge and observations about clinical cirrhosis trends in recent years related to the COVID-19 pandemic, namely more severe cases and rising mortality during and after the COVID-19 pandemic, highlighting the need for better risk stratification and patient management. The **3-min long video** features Dr. med. Julian Pohl (Charité – Universitätsmedizin Berlin) at his poster at the 2024 Congress of the European Association for the Study of the Liver (EASL) in Milan (poster SAT-452).

The three videos were planned in close collaboration with the speakers, recorded, produced (including professional subtitles), and published by WP7 leader concentris research management (concentris). The videos can be found under "[For Patients](#)" and "[Results](#)" on the project website. In addition, they are part of the "[A-TANGO Playlist](#)" on the [concentris YouTube channel](#) (580 subscribers, 5,763 views of A-TANGO videos, 99,938 impressions) and also available on the [A-TANGO YouTube channel](#) (22 subscribers, 1,023 video views, 13,086 impressions). The videos are contributions to a larger, openly accessible video portfolio created throughout the project that also includes five A-TANGO Masterclass lectures targeted to early-career scientists and five A-TANGO patient-scientist interviews targeted to liver patients.




Figure 1. Key visuals of the concentris YouTube channel (left) and the A-TANGO YouTube channel (right).

2 Introducing G-TAK, a novel combinatorial therapy for cirrhosis & ACLF (Video 1)

Video description on YouTube:

A-TANGO project website: <https://a-tango.eu/>

Effective treatment of acute-on-chronic liver failure (ACLF) is an urgent and unmet need. The A-TANGO consortium tests and evaluates an innovative new treatment that aims to reduce inflammation and improve hepatocyte proliferation by repurposing TAK-242, an antagonist of toll-like receptor 4, in combination with G-CSF (granulocyte colony-stimulating factor). We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Here, the clinical trial supervisor, Dr. med. Cornelius Engelmann, explains the different stages of liver cirrhosis and how this novel #combinatorial #treatment #therapy G-TAK, may increase the #survival rate of patients suffering from decompensated #cirrhosis or #ACLF. The video is a recording of the 3rd presentation given at an online patient event that was jointly organised by ELPA (<https://elpa.eu/>) and EF CLIF (<https://efclif.com/>) and took place on 9th June 2021.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096. This video reflects only the presenter's view and the European Commission is not responsible for any use that may be made of the information it contains.

Video URLs (URL = uniform resource locator)

- concentris channel: https://youtu.be/5aVZe_CJpps
- A-TANGO channel: <https://youtu.be/nlRdb72EiOY>
- Date of publication: **31 August 2021**

Number of video views

- concentris channel: **620**
- A-TANGO channel: **210**

Number of impressions

- concentris channel: **10,185 (10.2 K)**
- A-TANGO channel: **2,285 (2.3 K)**



Figure 2. Thumbnail of video 1.

3 Alcohol-related liver failure versus infection-induced ACLF (Video 2)

Video description on YouTube:

A-TANGO project website: <https://a-tango.eu/>

About A-TANGO: Effective treatment of acute-on-chronic liver failure (#ACLF) is an urgent and unmet need. The A-TANGO consortium tests and evaluates an innovative new treatment that aims to reduce inflammation and improve hepatocyte proliferation by repurposing TAK-242, an antagonist of toll-like receptor 4, in combination with G-CSF (granulocyte colony-stimulating factor). We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

About this video: In this collaborative presentation of A-TANGO's first major early-career scientists' (ECS) poster, Annarein Kerbert, a medical doctor (MD, PhD) at Leiden University Medical Center (LUMC), and Julian Pohl, a medical doctor (MD) at the Charité in Berlin, reveal the different clinical profiles of patients with alcohol-related ACLF versus infection-induced ACLF at the annual congress of the European Association for the Study of the Liver (#EASLCongress 2024) in Milan, Italy (poster number: THU-057-YI).

The A-TANGO project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096. This video reflects only the presenter's view and the European Commission is not responsible for any use that may be made of the information it contains.

Video URLs

- concentris channel: <https://youtu.be/i2VzyPldS4E>
- A-TANGO channel: <https://youtu.be/7rnM-Cgl33U>
- Date of publication: **05 July 2024**

Number of video views

- concentris channel: **90**
- A-TANGO channel: **63**

Number of impressions

- concentris channel: **1,552 (1.6 K)**
- A-TANGO channel: **695**



Figure 3. Thumbnail of video 2.

4 Evolving patterns in the clinical burden of liver cirrhosis (Video 3)

Video description on YouTube:

A-TANGO project website: <https://a-tango.eu/>

About A-TANGO: Effective treatment of acute-on-chronic liver failure (#ACLF) is an urgent and unmet need. The A-TANGO consortium tests and evaluates an innovative new treatment that aims to reduce inflammation and improve hepatocyte proliferation by repurposing TAK-242, an antagonist of toll-like receptor 4, in combination with G-CSF (granulocyte colony-stimulating factor). We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

About this video: Here, Julian Pohl, a medical doctor at Charité in Berlin, presents a study on cirrhosis trends at the annual Congress of the European Association for the Study of the Liver (#EASLCongress 2024) in Milan, Italy (poster number: SAT-452). The study - an ancillary study of the A-TANGO project - revealed overall decreasing #cirrhosis #hospitalization numbers since 2017 but more severe cases and rising #mortality rates over the past 5 years, especially during and after the #COVID19 pandemic, underscoring the need for improved risk stratification and patient management strategies.

The A-TANGO project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096. This video reflects only the presenter's view and the European Commission is not responsible for any use that may be made of the information it contains.

Video URLs

- concentris channel: <https://youtu.be/aNFgtbKUZEw>
- A-TANGO channel: <https://youtu.be/lxW7KH0IAg0>
- Date of publication: **08 July 2024**

Number of video views

- concentris channel: **42**
- A-TANGO channel: **40**

Number of impressions

- concentris channel: **544**
- A-TANGO channel: **444**



Figure 4. Thumbnail of video 3.

5 Conclusion

The three A-TANGO project videos successfully fulfil the objectives of this WP7 deliverable by communicating new knowledge on G-TAK and recent A-TANGO scientific outputs to patient communities, clinical hepatologists, early-career scientists, and other stakeholders. Across the concentris and A-TANGO YouTube channels, the three videos accumulated **1,065 (1.1 K) views** and **15,705 (15.7 K) impressions** in total, demonstrating a solid reach and engagement. As anticipated, the introductory video (Video 1) from 2021, addressing broad clinical and patient-relevant topics, achieved the greatest visibility (**830 views** and **12,470 impressions**), reflecting significant interest in ACLF treatment innovation and the strategic involvement of high-profile speakers.

When evaluated in relation to typical communication outputs from comparable Horizon 2020 biomedical projects - where short scientific videos frequently achieve modest view counts, often below 200 unless tied to large-scale public events - the performance of A-TANGO, particularly of Video 1, is competitive and in several respects above average. Moreover, these videos contribute to a broader and growing online dissemination portfolio, complementing the **6,786 (6.8 K) video views** and **113,024 (113 K) impressions** of A-TANGO-funded videos across both the concentris and the A-TANGO YouTube channel. This cumulative reach highlights the value of integrating multiple video-based communication formats and demonstrates continued dissemination impact as the project progresses.

Overall, our results confirm that video-based outreach represents an effective dissemination tool for engaging diverse stakeholder communities, reinforcing awareness of the unmet clinical need in ACLF, and enhancing visibility for the therapeutic potential of G-TAK. Sustained promotion efforts, particularly in connection with upcoming trial milestones and conference presentations, are expected to further expand reach and engagement.

6 Acknowledgement and Disclaimer



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096. This report reflects only the authors' view and the European Commission (EC) is not responsible for any use that may be made of the information it contains.